Results 71 to 80 of about 24,414 (214)

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels

Journal of Lipid Research, 2010
Over the past several years, proprotein convertase subtilisin kexin type 9 (PCSK9) has gained significant attention as a key regulator of serum LDL-cholesterol (LDL-C) levels.
Jason S. Troutt, William E. Alborn, Guoqing Cao, Robert J. Konrad   +3 more
doaj   +1 more source

Proprotein convertase subtilisin/kexin type 9 inhibitors: prospects for cholesterol-lowering therapy in type 2 diabetes

Mìžnarodnij Endokrinologìčnij Žurnal, 2023
Diabetic dyslipoproteinemia (DLP), characterized by quantitative, qualitative, and kinetic changes in all major circulating lipids, contributes to an increased risk of atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus (DM).
V.A. Serhiyenko, A.A. Serhiyenko
doaj   +1 more source

Impact of CYP2C19 Genotype Variants on PCSK9 Inhibitor Efficacy in Lipid‐Lowering Among Patients With Symptomatic Intracranial Atherosclerotic Stenosis

Lipids, EarlyView.
ABSTRACT Ischemic stroke is frequently associated with symptomatic intracranial atherosclerotic stenosis (sICAS), is a leading cause of global disability and mortality. Current guidelines recommend dual antiplatelet and intensive statin therapies. Proprotein convertase subtilisin 9/kexin type 9 (PCSK9) inhibitors have emerged as a potent lipid‐lowering
Chao Zhao, Nuan Wang, Di Shi, Hao Zhou, Dan Chen, Guofang Chen   +5 more
wiley   +1 more source

Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9

European Heart Journal, 2019
Aims Proprotein convertase subtilisin/kexin type-9 (PCSK9), a molecular determinant of low-density lipoprotein (LDL) receptor (LDLR) fate, has emerged as a promising therapeutic target for atherosclerotic cardiovascular diseases.
H. Jang, Sang Eun Lee, Jimin Yang, Hyun-Chae Lee, Dasom Shin, H. Lee, Jaewon Lee, Sooryeonhwa Jin, Soung-Hoon Kim, Seung Ji Lee, Jihye You, Hyun-Woo Park, Ky-Youb Nam, Sang-Hak Lee, Sahng-Wook Park, Jin-Soo Kim, Sang‐Yeob Kim, Y. Kwon, S. Kwak, Han-Mo Yang, Hyo‐Soo Kim   +20 more
semanticscholar   +1 more source

Proprotein convertase subtilisin/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus

Therapeutic Advances in Musculoskeletal Disease, 2020
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that regulates cholesterol metabolism through low-density lipoprotein receptor degradation and that has been linked to cardiovascular (CV) disease.
H. Sánchez-Pérez, J. C. Quevedo-Abeledo, B. Tejera-Segura, L. de Armas-Rillo, Í. Rúa-Figueroa, M. González-Gay, I. Ferraz-Amaro   +6 more
semanticscholar   +1 more source

Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach

Obesity, EarlyView.
Guidance recommendations by TOS/OMA/OAC for the use of obesity medications to treat obesity and its complications. ABSTRACT Background Obesity affects over 40% of US adults, with severe obesity on the rise. Despite recognition of obesity as a chronic disease, it remains underdiagnosed and undertreated.
Lydia Alexander, Jonathan Q. Purnell, Karlijn Burridge, Marc‐André Cornier, Angela Golden, Deborah Bade Horn, Michelle Look, Joe Nadglowski, Camila Ávila‐Oliver, Francisco Novillo, Ana María Rojas‐Gómez, Brad Hussey, Ximena Ramos Salas   +12 more
wiley   +1 more source

ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING

Инновационная медицина Кубани, 2019
Objectives. To estimate the relationship of proprotein convertase subtilisin/kexin type 9 (PCSK9) level with blood pressure (BP) and smoking in a population of young males in Novosibirsk.Material and methods.
K. S. Benimetskaya, M. P. Yachmeneva, S. V. Astrakov, L. V. Shcherbakova, D. V. Denisova, Yu. I. Ragino, M. I. Voevoda   +6 more
doaj   +2 more sources

Monogenic and syndromic obesity in children: Clinical recognition, genetics, and precision management

Pediatric Investigation, EarlyView.
Monogenic and syndromic obesity in children often arises from defects in the leptin–melanocortin pathway. Understanding these rare genetic causes not only clarifies mechanisms of appetite regulation but also enables precision therapies, offering hope beyond lifestyle interventions.
Hadel Khalil, Eugene Feigin, Hussein Zaitoon   +2 more
wiley   +1 more source

Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression

Journal of Biological Chemistry, 2020
Ascorbic acid, a water-soluble antioxidant, regulates various biological processes and is thought to influence cholesterol. However, little is known about the mechanisms underpinning ascorbic acid-mediated cholesterol metabolism.
Dandan Wang, Xiaoxiao Yang, Yuanli Chen, Ke Gong, Maoyun Yu, Yongyao Gao, Ximei Wu, Huaqing Hu, Chenzhong Liao, Jihong Han, Yajun Duan   +10 more
semanticscholar   +1 more source

Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice

Arteriosclerosis, Thrombosis and Vascular Biology, 2020
Supplemental Digital Content is available in the text. Objective: Increased postprandial lipemia (PPL) is an independent risk factor for atherosclerotic cardiovascular diseases.
D. Garçon, F. Moreau, A. Ayer, W. Dijk, X. Prieur, L. Arnaud, Anna Roubtsova, N. Seidah, A. Prat, B. Cariou, C. Le May   +10 more
semanticscholar   +1 more source